Characteristics of vitamin K-dependent carboxylating systems from human liver and placenta  by Soute, Berry A.M. et al.
Volume 146, number 2 FEBS LETTERS September 1982 
Characteristics of vitamin K-dependent carboxylating systems from human 
liver and placenta 
Berry A.M. Soute, Menno de Metz and Cees Vermeer* 
Department of Biochemistry, State University of Limburg, P.O. Box 616, 6200 M D Maastricht, The Netherlands 
Received 12 August 1982 
Bovine liver vitamin K-dependent carboxylase was compared with that obtained from human liver and 
placenta. Human liver microsomal preparations contained more endogenous substrate than did bovine 
preparations, but no differences were found between the two types of hepatic enzyme. This observation 
demonstrates that the bovine liver carboxylating enzyme system is a good model system which will help us 
to understand vitamin K action in man. Placental carboxylase differed from the liver systems because only 
vitamin K hydroquinone and not vitamin K quinone could be used as a coenzyme for the carboxylation 
reaction. Obviously, vitamin K reductase was absent in these preparations. 
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1. INTRODUCTION 
The four vitamin K-dependent clotting factors 
are synthesized in the liver, and during their syn- 
thesis they undergo a number of post-translational 
modifications, one of which is the vitamin K-de- 
pendent carboxylation of a number of glutamic 
acid residues [1,2]. The in vivo carboxylation reac- 
tion is inhibited by the oral administration of vi- 
tamin K-antagonists uch as warfarin or di- 
coumarol. This kind of treatment (anticoagulant 
therapy) is frequently used in medical practice and 
results in the production of non-carboxylated clot- 
ting factors (descarboxyfactors), which cannot be 
activated in the normal coagulation process [3]. 
Obviously, it became more interesting to investig- 
ate the mechanism of action of vitamin K as well 
as that of vitamin K-antagonists. In vitro model 
systems were developed from rat and bovine liver 
[4,5], from rat lung [6] and from horse spleen and 
kidney [7]. It is evident, that the results obtained 
with these model systems hould be compared with 
carboxylating systems from human origin. A first 
attempt was made by Friedman et al. [8], who pre- 
pared carboxylase from human placenta. As com- 
pared with rat liver carboxylase, the activity of this 
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system was very low, however. Here, we describe 
the preparation of carboxylase from human liver 
and placenta nd these two systems are compared 
with the formerly characterized bovine liver car- 
boxylase [5]. 
2. MATERIALS AND METHODS 
Vitamin K was obtained from Hoffmann-La 
Roche and vitamin K hydroquinone was prepared 
as in [5]. The synthetic substrate Phe-Leu-G lu -  
Glu-Leu (FLEEL) was obtained from Vega Fox 
and NaHI4CO3 (40 Ci/mol) from New England 
Nuclear. Triton X-100, warfarin, /3-mercaptoeth- 
anol, dithiothreitol (DTT) and dithioerythritol 
(DTE) were purchased by Sigma and NADH and 
NADPH by Boehringer Mannheim. Fragment Su 
was prepared from purified descarboxyprothrom- 
bin [9] and bovine carboxylase from normal cow 
liver [5]. Carboxylase from human liver was pre- 
pared in a similar way. Human livers were ob- 
tained from normal, healthy donors, who had died 
after traffic accidents and who had previously 
signed a donor-codicil. It was verified that they 
had not recently been under medical treatment, 
and that they had not received anti-vitamin K 
drugs. Carboxylase from term human placentae 
was prepared from the microsomal fraction of 
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trophoblast in a similar way as was carboxylase 
from bovine liver, except hat the microsomal sus- 
pension was solubilized with 0.12% Triton X-100. 
Carboxylase activity was measured in the presence 
of 10 mM FLEEL [5]. Unless stated otherwise, the 
carboxylation is expressed as the sum of the 14CO2 
incorporation into endogenous and exogenous 
substrate. Human prothrombin and clotting factor 
X were purified as in [10] and [11] and antibodies 
against hese proteins were raised in rabbits. 
3. RESULTS 
The optimal reaction conditions for the 3 Car- 
boxylating systems were similar: pH 7.5, 25°C, 
0.8 M KC1, 10 mM DTT and 10 mM MnCI2. In all 
3 systems the presence of MnC12 stimulated the 
carboxylation -2-fold. The K m of the pentapetide 
FLEEL, which was used as an exogenous ub- 
strate, was -8  mM in all cases. Liver carboxylase 
could be solubilized with 0.5% Triton X-100, but 
placental carboxylase was rapidly inactivated at 
these detergent concentrations. The best results 
were obtained with. 0.12% Triton X-100, which did 
not inactivate carboxylase and solubilized -60% 
of the total amount of enzyme. The Km values of 
vitamin K and vitamin K hydroquinone were mea- 
sured in the various systems. These values were 
closely similar in bovine and human liver (table 1), 
but when we tried to measure the Km of vitamin K 
in placental carboxylase, it resulted that this en- 
zyme system was absolutely dependent on the 
presence of vitamin K hydroquinone. No activity 
could be detected in the presence of vitamin K 
quinone. Obviously the vitamin K reductase in 
these preparations was either absent or inactive. It 
might also be assumed that vitamin K reductase is
present in the placental system, but that it has a 
high specificity towards some reducing agent. 
Therefore we replaced DTT (which is normally 
present in our reaction mixtures) by either DTE, fl- 
mercaptoethanol, NADH or NADPH, but none of 
these reducing agents were able to stimulate the 
vitamin K-dependent carboxylation. When we 
measured the amounts of endogenous substrate in 
the various preparations, a striking difference was 
observed between carboxylase from human liver 
and the other two preparations. Because all 3 
tissues had been obtained from normal, non-anti- 
coagulated subjects, it was to be expected, that 
hardly any endogenous substrate was present in 
either of these preparations. Nevertheless, it is ob- 
vious that the microsomal preparations from 
human liver contained substantial amounts of en- 
dogenous ubstrate (table 2), all of which was pres- 
ent in the trichloroacetic a id-precipitable fraction. 
We tried to identify this substrate using Sepharose- 
bound antibodies against human prothrombin and 
factor X. It resulted, that from the total amount of 
carboxylated product 45% could be bound to anti- 
factor X and 21% to antiprothrombin. 
We also investigated the substrate specificities of 
the various systems for carboxylatable exogenous 
substrates such as FLEEL and fragment Su. Both 
substrates are derived from bovine descarboxy- 
prothrombin: while the synthetic pentapeptide r - 
sembles the amino acid residues 5-9, fragment Su 
is similar to the residues 13-29. FLEEL contains 
the first 2 carboxylatable Glu-residues in des- 
carboxyprothrombin a d fragment Su the subse- 
quent 6 ones. As is shown in table 3, the Km of 
fragment Su ranged from 0.8-1.0/tM in the 3 dif- 
Table 1 
Characteristics ofcarboxylase from different tissues 
Source of Km (~M) of: 
carboxylase 
Vitamin K Vitamin KH2 
Warfarin concentration (ttM) required 
for 50% inhibition in presence of: 
Vitamin K (25/tM) Vitamin KH 2 (25/tM) 
Bovine liver 13 10 2 400 
Human liver 16 22 3 1500 
Human placenta - 16 - 1200 
All tests were performed under standard conditions. Vitamin K hydroquinone is abbreviated 
as vitamin KH 2 
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Table 2 
Amounts of enzyme and endogenous substrate in carboxylase from different 
tissues 
Source of Carboxylase Endogenous substrate 
carboxylase (dpm/min, mg protein) (dpm/mg protein) 
Bovine liver 31 0 
Human liver 95 1120 
Human placenta 12 0 
The amount of carboxylase was measured as the carboxylation rate in endogenous 
+ exogenous substrate (FLEEL, 10 mM) and is expressed as dpm per min and per 
mg protein. The amount of endogenous substrate is given as the total amount of 
14CO2 (dpm/mg protein) that could be incorporated into trichloroacetic acid- 
precipitable material. This way of quantitating carboxylase and its endogenous 
substrate isexplained extensively in [5] 
Table 3 
Kinetic parameters in carboxylase from different tissues 
Source of FLEEL Fragment Su 
carboxylase Km (mM) V(dpm/min, mg) K m (/~M) V(dpm/min, mg) 
Bovine liver 3.3 108 1.0 24.6 
Human liver 2.8 99 0.8 35.5 
Human placenta 7.1 I4.3 0.9 13.5 
The K m and the maximal carboxylation rate V are calculated as in [9]; V is 
expressed as dpm per min and per mg microsomal protein 
ferent ypes of preparations. The Km of FLEEL on 
the other hand, was 2.5-times higher in placental 
carboxylase than in the liver systems, suggesting 
that the pentapeptide is recognized less efficiently 
by placental carboxylase than by the liver enzyme. 
In placental carboxylase the maximal rate of sub- 
strate carboxylation V was similar for both sub- 
strates. In the liver systems, however, the carboxyl- 
ation rate of FLEEL was 3-4-times higher than 
that of fragment Su. 
4. DISCUSSION 
Here we describe the vitamin K-dependent car- 
boxylation in microsomal preparations obtained 
from normal bovine liver, from human liver and 
from human placenta. When comparing the 
bovine and human liver systems, we observed that 
they were similar except hat the human prepara- 
tions contained substantial amounts of endo- 
genous substrate. That both enzyme systems are 
similar, supports the idea that animal model sys- 
tems will help us in understanding vitamin K ac- 
tion in man. The amounts of endogenous substrate 
in human liver were comparable to those in livers 
from warfarin-treated cows. This phenomenon was 
observed in 3 successive humanqivers, whereas in 
> 10 normal bovine livers we have never been able 
to detect comparable amounts of substrate [5]. We 
concluded, that in these human livers the produc- 
tion of endogenous ubstrate had occurred at a 
higher speed than had the carboxylation reaction. 
This might be due, either to a vitamin K deficiency 
or to a limiting amount of carboxylase. Vitamin K 
deficiency is not a common feature in man and 
moreover, it was not observed in placental car- 
boxylase. We think, therefore, that the abnormal 
high level of clotting factor precursors in human 
liver is a result of the physical condition of the 
donors at the moment that the livers were ob- 
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tained: all donors had gone through a traffic acci- 
dent, attended with severe brain damage, massive 
blood loss and diffuse intravascular nd other co- 
agulation processes. After hospitalization, they 
were ventilated for at least 4-8 h before excision 
of their livers. Because blood loss, decreased plas- 
ma concentrations of clotting factors and activa- 
tion products of clotting factors [12,13] all have 
been reported to stimulate the de novo synthesis of 
clotting factors, it is likely that also in the human 
livers, described here, the production' of clotting 
factors had been strongly enhanced. It is known 
that other post-translational enzymes (e.g., pro- 
lylhydroxylase, lysylhydroxylase, glucosyltrans- 
ferase and galactosyltransferase) are present in 
only marginal quantities [14]. The same may be 
the case for carboxylase, and this would explain 
why during periods of an unusual high production 
of clotting factor precursors, the latter accumulate 
in the liver. In such a situation the carboxylation 
(or maybe the combined post-translational pro- 
cesses) is the rate-limiting step in their maturation. 
Since we do not have further evidence to support 
this theory, other explanations may be given for 
the high amounts of endogenous ubstrate in 
human liver. When we compared carboxylase in 
liver and placental microsomes the placental prep- 
arations eemed to contain carboxylase but no re- 
ductase: only vitamin K hydroquinone and not vi- 
tamin K quinone was able to stimulate the carbox- 
ylation reaction. Since the placental carboxylating 
system in [8] was only tested with vitamin K 
quinone, this explains why these authors observed 
such a low activity. It is not likely, that also in vivo 
the reducing enzyme system is absent, so we think 
that it is lost and/or destroyed somewhere during 
the preparation procedure. It is remarkable, that 
the differences in substrate specificity between the 
various carboxylases are so low. Only in the case of 
FLEEL we observed a slightly increased Km in the 
placental system. It seems plausible, that a univer- 
sal mechanism for substrate recognition is opera- 
tive in carboxylase from various types of tissue. 
The differences between the maximal carboxyla- 
tion rates in the 3 systems may partially be brought 
about by differences between the amounts of car- 
boxylase/mg microsomal protein in the various 
tissues. On the other hand, the relation between V 
in liver microsomes and that in placental micro- 
somes varies with the choice of the substrate. So it 
seems, that the differences between the kinetic pa- 
rameters in the 3 tissues indicate some substrate 
specificity of the various enzyme systems, but the 
differences are too small to draw definite con- 
clusions as yet. 
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